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RECOMBINANT BACULOVIRUS:  
AuNPV 
 
HOSTE RANGE:  
Invertebrates 
 
CELL LINE: 
 
BTI-TN-5B1-4  
(HighFive Cells) 
  
 
             
  
◊ 6 batch of cellular  scale up 
and reaction  
     (12 days/batch) 
 
◊ 1 batch of viral 
amplification  
    (3 days/batch) 
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Design of an industrial bioprocess plant with the simulator SuperPro 
Designer for the production of the equine influenza vaccine using a 
baculovirus expression system in insect cell lines, and subsequent 
analysis of its sustainability. 
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2 INFLUENZA STRAINS  
 (15 μg HA1/strain) 
  
REACTION:  
 
 Solution: Parameters 
control 
 
CHAIN BATCHES:  
 
 Solution: 1 week per 
month slack time 
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HA1 
heterologous 
expression 
lacZ 
mini-att Tn7 [3] 
[1] [2] 
Uses baculovirus as a vector to express                                                   
heterologous genes in insect cell cultures 
under the control of strong promoters.  
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NUTRIENTS STREAMS 
Commercial powder 
medium dissolved in water 
and enriched with  
L-glutamine and Pluronic 
 F-68. 
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